Low-Cost B-Cell Depleting Therapy Shows Equal Effectiveness to Standard Treatment for Multiple Sclerosis

A Norwegian-Swedish clinical trial, OVERLORD-MS, published in The New England Journal of Medicine, has demonstrated that rituximab, a low-cost B-cell depleting therapy, is as effective as ocrelizumab in newly diagnosed relapsing multiple sclerosis (MS). The study, which followed patients for 30 months, found comparable efficacy and safety between the two treatments, suggesting that effective MS treatment can be delivered at a dramatically lower cost without compromising patient outcomes.